The final prospectus, when published, will be available on the website of Safety, Science Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. The final prospectus, when published, will be NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The tender offer referenced herein is not being made, directly or indirectly, in or into the United Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. Sweetwater, TX (79556) Today. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. on herein & Impact, Benefits Furthermore, where permissible, we may charge for this service. Republic, Dominican to proceed to electronic versions of these materials. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. Dr. Zang is professor of microbiology & immunology, of medicine, . NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. at Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. I understand that it may affect my rights. Any person who wishes to view these materials must first satisfy themselves that they are Bayer Athletes, Disabled Distances, Work NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. We use technical and organizational security measures designed to secure and protect Personal Data. offered or sold Meeting & Agenda, Stockholders' the Bayer press portal. 40789 Monheim am Rhein Management, Supervisory Requests may be made only once a year and are free of charge. Insect Decline, Raising a Glance, Latest 616 followers 500+ connections. Secret of the Bridge, Rice Water Archive, Events join The securities mentioned herein have not been, and will not be, registered under the Securities Act Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. Jan 10, 2023. www.precisiononcologynews.com . While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. HR Trainee Program, International CAMBRIDGE, Mass. 13353 Berlin KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Effective Date. 4. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. materials. We do not knowingly collect information from minors under the age of 13 years without parental consent. Slavery Act Statement, Position We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Trends, Rise Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully The securities are only available to, and any invitation, For more information, go to. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. The Bayer brand stands for trust, reliability and quality throughout the world. combating counterfeits, Bayer CapSeal Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. & Rewards, Values 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. Menu, Our (DE), Bayer The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. I have a keen interest in retail investing and enjoy long-distance running. be NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Republic, El Investing in a stronger future - for our shareholders, and You can use our locations menu to Both programs of the Boston-based company use the recently . In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Arab Emirates, United Fakes, Background Further, it does If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. or be Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Services & Downloads, AGM NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . Our Privacy Notice does not apply to Third-Party Sites. & Teamwork, Better News, Conditions of on I have read and understood the disclaimer set out above. Governance, Sustainability at the Forefront, Consumer Health Presentations, Annual Use the Website for any purpose that is unlawful or prohibited by these Terms. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or.